Menu
← Oncology Approval Tracker
FDA DECISION ·
Erbitux + Braftovi
cetuximab with encorafenib · ImClone / Array BioPharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with BRAF V600E-mutated metastatic colorectal cancer by an FDA-approved test after prior therapy.
LAMPGEN ANALYSIS
Why it matters
This approval adds the targeted combination to the cetuximab label after its prior approval on the encorafenib label.
What research teams should watch
Verify the BRAF substitution and prior treatment and use each product’s actual action date in the tracker.
PRIMARY RECORDS